- Poster presentation
- Open Access
One-year observation of leflunomide effectiveness and saftey in juvenile idiopathic arthritis : a clinical practice review (preliminary data)
© Torrente-Segarra et al; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Juvenile Idiopathic Arthritis
To assess efectiveness and safety of leflunomide (LFN) in juvenile idiopathic arthritis patients (JIA).
We performed a retrospective medical charts review in all JIA patients who received LFN between Jan 2006 to Mar 2011 from our outpatient Pediatric Rheumatology Clinics. We collected data of: gender, age, type of JIA, date of onset, date of diagnosis, date of first DMARD, uveitis, reason to indiciate LFN, concomitant therapies, reason to discontinuation, joint activity (tender and swollen, low rang of motion count), and biological markers at baseline, 3 and 12-months follow-up.
71% of patients who received LFN showed efficacy and only 14% had adverse events (recovered). Most were ANA positive oligoarticular JIA, and 2 more had uveitis.
Safety seemed acceptable either alone or with antiTNF concomitant use.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.